JPH07100719B2 - Colony-stimulating factor and method for producing the same - Google Patents

Colony-stimulating factor and method for producing the same

Info

Publication number
JPH07100719B2
JPH07100719B2 JP61291294A JP29129486A JPH07100719B2 JP H07100719 B2 JPH07100719 B2 JP H07100719B2 JP 61291294 A JP61291294 A JP 61291294A JP 29129486 A JP29129486 A JP 29129486A JP H07100719 B2 JPH07100719 B2 JP H07100719B2
Authority
JP
Japan
Prior art keywords
molecular weight
csf
spectrum
amino acid
measured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP61291294A
Other languages
Japanese (ja)
Other versions
JPS63198700A (en
Inventor
史麿 高久
和夫 元吉
拓司 川島
実 斉藤
延也 柳内
宗夫 山田
肇 横田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morinaga Milk Industry Co Ltd
Original Assignee
Morinaga Milk Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morinaga Milk Industry Co Ltd filed Critical Morinaga Milk Industry Co Ltd
Priority to JP61291294A priority Critical patent/JPH07100719B2/en
Priority to AU82181/87A priority patent/AU606099B2/en
Priority to DE8787310739T priority patent/DE3777623D1/en
Priority to AT87310739T priority patent/ATE73825T1/en
Priority to EP87310739A priority patent/EP0276551B1/en
Priority to KR1019880003849A priority patent/KR960005731B1/en
Publication of JPS63198700A publication Critical patent/JPS63198700A/en
Publication of JPH07100719B2 publication Critical patent/JPH07100719B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【発明の詳細な説明】 [産業上の利用分野] 本発明は人尿から分離され、哺乳動物の単球−マクロフ
アージ系細胞のコロニー形成を刺激する新規なコロニー
刺激因子とその製造法に関するものである。
TECHNICAL FIELD The present invention relates to a novel colony stimulating factor isolated from human urine and stimulating colony formation of mammalian monocyte-macrophage cells, and a method for producing the same. is there.

[従来の技術] コロニー刺激因子(以下CSFと略記する)は、哺乳動物
の造血組織、例えば骨髄などに存在する造血幹細胞の分
化・増殖を刺激する造血因子であり、多くのCSFは糖蛋
白質から成つている。これまで、単球−マクロフアージ
系幹細胞に作用する因子(M−CSF又はCSF−1)、顆粒
球−単球系幹細胞に作用する因子(GM−CSF)、顆粒球
系幹細胞に作用する因子(G−CSF)、更に顆粒球、単
球、赤血球及び巨核球に共通な多能性幹細胞に作用する
因子(Multi−CSF、インターロイキン−3又はIL−3)
の4種が知られている。
[Prior Art] A colony-stimulating factor (hereinafter abbreviated as CSF) is a hematopoietic factor that stimulates the differentiation and proliferation of hematopoietic stem cells present in mammalian hematopoietic tissues such as bone marrow, and many CSFs are derived from glycoproteins. It is made up. So far, factors that act on monocyte-macrophage stem cells (M-CSF or CSF-1), factors that act on granulocyte-monocyte stem cells (GM-CSF), and factors that act on granulocyte stem cells (G -CSF), and factors that act on pluripotent stem cells common to granulocytes, monocytes, erythrocytes and megakaryocytes (Multi-CSF, interleukin-3 or IL-3)
4 kinds of are known.

Multi−CSFを除く上記3種の人由来CSFは、それぞれの
アミノ酸配列をコードする遺伝子cDNAがクローニングさ
れており、蛋白質構造が明らかにされている[G.G.Wong
ら,Science,228巻,810〜815頁,1985年;E.S.Kawasaki
ら、Science,230巻,291−296頁、1985年;S.Nagataら,Na
ture,319巻,415−418頁,1986年]。
Except for Multi-CSF, the above-mentioned three kinds of human-derived CSF have cloned gene cDNAs encoding the respective amino acid sequences, and their protein structures have been clarified [GGWong
Et al., Science, 228, 810-815, 1985; ES Kawasaki
Et al., Science, 230, 291-296, 1985; S. Nagata et al., Na.
ture, 319, 415-418, 1986].

人尿中に存在するCSFとしては、単球−マクロフアージ
系細胞に作用する因子(CSF−1又はM−CSF)[S.K.Da
s & E.R.Stanley,Journal of Biological Chemistry,2
57巻,13679〜13684頁,1982年]、顆粒球コロニーを刺激
するHGI−糖蛋白質[特公昭60−30291号公報]及びCSF
−HU[K.Motoyoshiら,Blood,52巻,1012〜1020頁,1978年
及びBlood,60巻,1378〜1386頁,1982年]が報告されてい
る。
As CSF present in human urine, factors acting on monocyte-macrophage cells (CSF-1 or M-CSF) [SKDa
s & ERStanley, Journal of Biological Chemistry, 2
57, 13679-13684, 1982], HGI-glycoprotein that stimulates granulocyte colony [Japanese Patent Publication No. 60-30291] and CSF.
-HU [K. Motoyoshi et al., Blood, 52, 1012-1020, 1978 and Blood, 60, 1378-1386, 1982] have been reported.

それらのうち、単球−マクロフアージ系細胞に作用する
上記CSF−1は完全に鈍化され、またその蛋白質をコー
ドするcDNAがクローニングされている(上記、E.S.Kawa
sakiら)。
Among them, CSF-1 acting on monocyte-macrophage cells is completely blunted, and the cDNA encoding the protein has been cloned (ESKawa, supra).
saki et al.).

鈍化CSF−1の構造は、糖鎖を含む二本のポリペプチド
がジスルフイド結合により、生物学的に活性なホモ2量
体を形成している。この2量体はジスルフイド結合を還
元剤により切断することにより同一の2個のサブユニツ
トを生成する。この生物学的活性を有する糖蛋白質の、
ドデシル硫酸ナトリウム・ポリアクリルアミド電気泳動
法により測定した分子量は、45,000〜60,000ダルトンで
ある。また2量体を形成するポリペプチドサブユニツト
の糖鎖を除いた分子量は14,000〜17,000ダルトンであ
る。このCSF−1サブユニツトのアミノ酸配列をコード
していると考えられるcDNAから推定されたアミノ酸数は
224個、分子量26,000ダルトンのポリペプチドである。
In the structure of blunted CSF-1, two polypeptides containing a sugar chain form a biologically active homodimer by disulphide bond. This dimer produces two identical subunits by cleaving the disulphide bond with a reducing agent. Of this glycoprotein with biological activity,
The molecular weight measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis is 45,000-60,000 daltons. The molecular weight of the polypeptide subunit forming the dimer, excluding the sugar chains, is 14,000 to 17,000 daltons. The number of amino acids deduced from the cDNA considered to encode the amino acid sequence of this CSF-1 subunit is
It is a polypeptide with 224 molecules and a molecular weight of 26,000 daltons.

[発明が解決しようとする問題点] 本発明者らは人尿中に、CSF−1と同様に作用するが、
理化学的にCSF−1とは区別される従来知られていなか
つた新規な糖蛋白CSFが存在することを見い出してこれ
を単離し、その理化学的及び生物学的性質を明らかにす
ることにより本発明を完成した。
[Problems to be Solved by the Invention] Although the present inventors act in human urine in the same manner as CSF-1,
The present invention was found by discovering the existence of a novel glycoprotein CSF, which has not been known so far, which is physicochemically distinguished from CSF-1, and has isolated it and clarified its physicochemical and biological properties. Was completed.

本発明の目的は、抗ガン剤化学療法による白血球減少
症、免疫不全及び骨髄移植等に治療効果がある新規なCS
Fとその製造法を提供することにある。
The object of the present invention is to provide a novel CS having a therapeutic effect on leukopenia, immunodeficiency, bone marrow transplantation, etc. due to anticancer drug chemotherapy.
To provide F and its manufacturing method.

即ち、本発明は、下記の理化学的性質を有し、且つ哺乳
動物の単球−マクロフアージ系細胞のコロニー形成刺激
作用を有する糖蛋白よりなる新規なCSFを提供する。
That is, the present invention provides a novel CSF consisting of a glycoprotein having the following physicochemical properties and having an action of stimulating colony formation of mammalian monocyte-macrophage cells.

a)分子量 CSF−1と同様に還元剤により同一のサブユニツト2個
に解離されるホモ2量体であり、ドデシル硫酸ナトリウ
ム・ポリアクリルアミドゲル電気泳動で測定した分子量
が70,000〜90,000ダルトンであつて、還元剤で解離さ
せ、生物活性を消失させたサブユニツトについてドデシ
ル硫酸ナトリウム・ポリアクリルアミドゲル電気泳動で
測定した分子量は35,000〜45,000ダルトンである。
a) Molecular weight It is a homodimer dissociated into two identical subunits by a reducing agent like CSF-1, and has a molecular weight of 70,000 to 90,000 daltons measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The molecular weight of the subunit, which had been dissociated with a reducing agent and had lost its biological activity, measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, was 35,000 to 45,000 daltons.

(b)サブユニツトのアミノ酸配列 ホモ2量体を構成するサブユニツト蛋白質は、次に示す
少なくとも189個のアミノ酸配列から成り、 122番目及び140番目のアスパラギン(Asn)はそれぞれ
アスパラギン(Asn)−X−スレオニン(Thr)又はセリ
ン(Ser)で表わされる典型的なN−グリコシド結合部
位を有する。ただしXは任意のアミノ酸を表わす。
(B) Subunit Amino Acid Sequence The subunit protein constituting the homodimer consists of at least 189 amino acid sequences shown below, The 122 and 140th asparagine (Asn) has a typical N-glycoside binding site represented by asparagine (Asn) -X-threonine (Thr) or serine (Ser), respectively. However, X represents an arbitrary amino acid.

c)等電点 ポリアクリルアミドゲル等電点電気泳動法及びシユクロ
ース密度勾配等電点電気泳動法で測定した等電点(pI)
は3.1〜3.7である。
c) Isoelectric point Isoelectric point (pI) measured by polyacrylamide gel isoelectric focusing method and sucrose density gradient isoelectric focusing method.
Is 3.1 to 3.7.

d)糖鎖の構成単糖 加水分解後高速液体クロマトグラフイーで分析し、糖鎖
の構成単糖として、マンノース、ガラクトース、N−ア
セチルグルコサミン及びN−アセチルノイラミン酸が同
定された。
d) Constituent monosaccharide of sugar chain After hydrolysis, analysis was performed by high performance liquid chromatography, and mannose, galactose, N-acetylglucosamine and N-acetylneuraminic acid were identified as constituent sugars of the sugar chain.

e)円二色性スペクトル 円二色性分散計による遠紫外部CDスペクトルは波長208n
m及び222nmにそれぞれ極少ピークがあり、α−ヘリツク
ス構造を含んでいる。
e) Circular dichroism spectrum The far-UV external CD spectrum measured by the circular dichroism dispersometer has a wavelength of
There are minimal peaks at m and 222 nm, respectively, and an α-helix structure is included.

f)熱安定性 60±0.5℃で60分間加熱しても生物活性は失なわれな
い; g)赤外線吸収スペクトル 第3図に示す赤外線吸収スペクトルを有する。
f) Thermal stability No biological activity is lost by heating at 60 ± 0.5 ° C. for 60 minutes; g) Infrared absorption spectrum It has the infrared absorption spectrum shown in FIG.

以上の理化学的性質を有することを特徴とするコロニー
刺激因子を含む人尿をpH8〜9に調整し、不溶物を沈澱
せしめ、その上澄を限外濾過膜で脱塩し、少なくとも20
0倍以上に濃縮した後、pHを6.5〜7.5に調整し、60℃で1
0時間加熱処理し、生ずる沈澱物を遠心除去後、陰イオ
ン交換体に吸着させ、0.2〜0.4M緩衝液で溶出させ、次
いで1〜4M緩衝液中でゲル濾過して分子量70,000ダルト
ン以上の画分を回収し、該画分を疎水性親和体に吸着さ
せて0.5〜1M緩衝液で溶出させ、該溶出物を高速液体ゲ
ル濾過にかけ、分子量70,000〜150,000ダルトンの画分
を回収し、該画分をpH1〜2に調整して逆相高速液体ク
ロマトグラフイーにかけ、有効成分を溶出せしめること
を特徴とするコロニー刺激因子の製造法である。
Human urine containing colony stimulating factors having the above physicochemical properties was adjusted to pH 8 to 9 to precipitate insoluble matter, and the supernatant was desalted with an ultrafiltration membrane to obtain at least 20
After concentrating to 0 times or more, adjust the pH to 6.5-7.5 and
After heat treatment for 0 hours, the resulting precipitate was removed by centrifugation, adsorbed on an anion exchanger, eluted with 0.2-0.4M buffer solution, and then gel-filtered in 1-4M buffer solution to give a fraction having a molecular weight of 70,000 daltons or more. The fraction was collected, the fraction was adsorbed to a hydrophobic affinity substance and eluted with 0.5 to 1 M buffer, and the eluate was subjected to high performance liquid gel filtration to collect a fraction having a molecular weight of 70,000 to 150,000 daltons. The method is a method for producing a colony stimulating factor, characterized in that the active ingredient is eluted by adjusting the pH to 1 to 2 and performing reverse phase high performance liquid chromatography.

[発明の具体的な説明] (1)CSFの製造 本発明のCSFは次のようにして製造される。[Detailed Description of the Invention] (1) Production of CSF The CSF of the present invention is produced as follows.

健康人の尿をpH8.0〜9.0に調整し、尿中の粘性物質を沈
澱・除去し、その上澄を分子量10,000〜50,000ダルトン
を通過させる限外濾過膜を用いて濃縮と脱塩を行う。
Adjust the urine of healthy people to pH 8.0 to 9.0, precipitate and remove the viscous substances in urine, and concentrate and desalt the supernatant using an ultrafiltration membrane that passes a molecular weight of 10,000 to 50,000 daltons. .

少なくとも200倍以上に濃縮(蛋白質濃度として1%(w
/v)以上)した後pHを6.5〜7.5に調整し、60℃で10時間
加熱処理(ウイルス等の不活化)する。形成された沈澱
物を遠心除去し、陰イオン交換体、例えばDEAE−セルロ
ース等、に有効成分を吸着させる。
Concentrate at least 200 times (1% protein concentration (w
/ v) or more), adjust the pH to 6.5 to 7.5, and heat at 60 ℃ for 10 hours (inactivate viruses, etc.). The precipitate formed is removed by centrifugation and the active ingredient is adsorbed on an anion exchanger such as DEAE-cellulose.

次に0.05〜0.1Mの緩衝液(pH6.5〜7.5)で該イオン交換
体を洗浄した後0.2〜0.4Mの緩衝液(pH6.5〜7.5)で有
効成分を溶出する。該溶出液を必要ならば限外濾過膜で
濃縮し、1M〜4Mの塩類、例えば硫安、食塩等を含有する
緩衝液(pH6.5〜7.5)で平衡化させたゲル濾過剤、例え
ばSephacryl S−300(Pharmacia社製)でゲル濾過
し、分子量範囲が70,000〜150,000ダルトンの画分を回
収する。次に該画分を上記1M〜4Mの塩含有緩衝液で平衡
化させた疎水性親和体、例えばPhenyl−Sepharose (P
harmacia社製)に吸着させ、0.5〜1.0Mの塩含有緩衝液
(pH6.5〜7.5)で溶出する。該溶出液を限外濾過膜で濃
縮し、高速液体ゲル濾過カラム、例えばTSKG−3000SW
(東洋曹達製)でゲル濾過し、分子量範囲が70,000〜15
0,000ダルトンの画分を回収する。該画分を再度、濃縮
し、0.1%トリフルオロ酢酸(TFA)溶液(pH1〜2)で
平衡化した高速液体逆相カラム、例えば、Hi−Pore RP
−304(バイオラド社製)に吸着させ、0.1%TFAを含む
溶剤、例えばアセトニトリル又はイソプロパノールの直
線濃度勾配溶出法により溶出する。このようにして得ら
れたCSFは、比活性1×108単位/mg・蛋白質以上を有す
る純粋な物質である。
Next, the ion exchange is performed with 0.05 to 0.1 M buffer (pH 6.5 to 7.5).
After washing the body, use 0.2-0.4M buffer (pH 6.5-7.5)
Elute the active ingredient. If necessary, use the ultrafiltration membrane for the eluate
Concentrate and contain 1M-4M salts such as ammonium sulfate, salt, etc.
Gel filtration agent equilibrated with buffer solution (pH 6.5 to 7.5), eg
By Sephacryl Gel filtration with S-300 (Pharmacia)
The fraction with a molecular weight range of 70,000 to 150,000 daltons.
To collect. The fractions were then equilibrated with the above 1M-4M salt-containing buffer.
Derivatized hydrophobic affinity, for example Phenyl-Sepharose (P
harmacia), 0.5-1.0M salt-containing buffer
Elute at (pH 6.5-7.5). The eluate was concentrated with an ultrafiltration membrane.
High-performance liquid gel filtration column, such as TSKG-3000SW
(Made by Toyo Soda Co., Ltd.) gel filtration, molecular weight range 70,000-15
Collect a fraction of 0,000 Daltons. Concentrate the fraction again
With 0.1% trifluoroacetic acid (TFA) solution (pH 1-2)
Equilibrated high-performance liquid reverse-phase column, such as Hi-Pore RP
Adsorbed on -304 (BioRad) and contains 0.1% TFA
A solvent such as acetonitrile or isopropanol
Elute by the linear gradient elution method. Obtained this way
CSF has a specific activity of 1 x 108More than unit / mg protein
It is a pure substance.

(2)CSFの理化学的性状 以上のようにして製造された本発明のCSFは次のような
理化学的性状を有している。尚、この理化学的性状の試
験には、実施例1の方法により純化したCSFを用いた。
(2) Physicochemical properties of CSF The CSF of the present invention produced as described above has the following physicochemical properties. In this physicochemical property test, CSF purified by the method of Example 1 was used.

(a)分子量 還元剤の非存在下に、Laemmli(Nature,227巻,680−685
頁,1970年)の方法によるドデシル硫酸ナトリウム・ポ
リアクリルアミド電気泳動で分子量を測定すると、70,0
00〜90,000ダルトンであつた。
(A) Molecular weight In the absence of a reducing agent, Laemmli (Nature, Vol. 227, 680-685)
Page, 1970), the molecular weight was 70,0 when measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
It was between 00 and 90,000 Daltons.

次に、0.2Mメルカプトエタノールで還元し、同様の方法
で測定すると、分子量35,000〜45,000ダルトンのサブユ
ニツトに解離した(第1図)。
Next, it was reduced with 0.2 M mercaptoethanol, and when measured by the same method, it was dissociated into subunits having a molecular weight of 35,000 to 45,000 daltons (Fig. 1).

第1図は、本発明のCSFのドデシル硫酸ナトリウム・ポ
リアクリルアミド電気泳動の泳動図であり、A〜Eは非
還元(2量体)、F,Gは分子量マーカー蛋白質、H〜L
は還元(サブユニツト)を示し、縦軸の数字は分子量
(×103ダルトン)を示す。
FIG. 1 is a electrophoresis diagram of CSF of the present invention by sodium dodecylsulfate / polyacrylamide electrophoresis, in which A to E are non-reducing (dimers), F and G are molecular weight marker proteins, and H to L.
Indicates reduction (subunit), and the number on the vertical axis indicates molecular weight (× 10 3 dalton).

(b)サブユニツト蛋白質のアミノ酸配列 NH2−末端アミノ酸配列は、純化CSFを気相アミノ酸シー
ケンサーで常法により分析した。次に純化CSFを6Mグア
ニジンで変性させ、モノヨード酢酸でアルキル化した
後、脱塩し、トリプシン消化を行なつた。トリプシン処
理ペプチドをVydac C−18逆相高速液体クロマトグラフ
イーで分画し、23のペプチド画分を得、各画分をそれぞ
れ気相アミノ酸シーケンサーで分析し、ペプチド断片の
アミノ酸配列を分析した。トリプシン消化ペプチド断片
のアミノ酸配列と本発明者らがクローニングしたmRNAの
塩基配列から、サブユニツト蛋白質のアミノ酸一次構造
を決定した。その結果は表1に示すとおりである。
(B) Sabuyunitsuto protein amino acid sequence of the NH 2 - terminal amino acid sequence was analyzed by a conventional method in the gas phase amino acid sequencer purified CSF. The purified CSF was then denatured with 6M guanidine, alkylated with monoiodoacetic acid, desalted and digested with trypsin. The trypsin-treated peptide was fractionated by Vydac C-18 reverse phase high performance liquid chromatography to obtain 23 peptide fractions. Each fraction was analyzed by a gas phase amino acid sequencer to analyze the amino acid sequence of the peptide fragment. The amino acid primary structure of the subunit protein was determined from the amino acid sequence of the tryptic digested peptide fragment and the nucleotide sequence of mRNA cloned by the present inventors. The results are shown in Table 1.

NH2−末端のアミノ酸であるグルタミン酸から149番目の
グルタミンまでは、公知のCSF−1と同一であるが、150
番目から189番目までの40個のアミノ酸は、公知のそれ
と全く異なつていた。またCOOH−末端アミノ酸であるロ
イシンの次に、少なくとも α,β,γの三個のアミノ酸の存在が定性され、αはス
レオニン、βはトリプトフアン、γはグルタミン酸であ
ることが予測された。122番目と140番目のアスパラギン
は、Asn−X−Ser/Thrの典型的なN−グリコシド結合構
造を有し、この部位で糖鎖を結合しているものと推定さ
れた。ここにXは任意のアミノ酸を示す。
NH 2 - From glutamate, amino terminal to the 149th glutamine is identical to the known CSF-1, 0.99
The 40 amino acids from position 1 to position 189 were completely different from the known ones. Also, at least next to the COOH-terminal amino acid leucine, The existence of three amino acids of α, β, and γ was qualitatively determined, and it was predicted that α is threonine, β is tryptophan, and γ is glutamic acid. The 122nd and 140th asparagine had a typical N-glycoside bond structure of Asn-X-Ser / Thr, and it was presumed that sugar chains were bonded at this site. Here, X represents an arbitrary amino acid.

(c)糖鎖の構成単糖 ポリペプチドと結合している糖鎖の構成単糖は、加水分
解して遊離させた後、高速液体クロマトグラフイーで分
析した。アルドース、シアル酸は陰イオン交換カラム、
ヘキソサミンは陽イオン交換カラムでホウ酸緩衝液濃度
勾配溶出法で分画し、シアノアセタミド又はアルギニン
によるポストカラム標識した後、ケイ光法により同定し
た。本CSF分子に含有される糖鎖は不均一であり、定量
することは困難であつたが、構成単糖としてマンノー
ス、ガラクトース、N−アセチルグリコサミン及びN−
アセチルノイラミン酸が同定された。そのモル比はおよ
そ2.5:1.4:2.5:2.1であつた。
(C) Constituent Monosaccharide of Sugar Chain The constituent monosaccharide of the sugar chain bound to the polypeptide was hydrolyzed and released, and then analyzed by high performance liquid chromatography. Aldose, sialic acid for anion exchange column,
Hexosamine was fractionated by a cation exchange column by a borate buffer gradient elution method, post-column labeled with cyanoacetamide or arginine, and then identified by a fluorescent method. Although the sugar chains contained in the CSF molecule were heterogeneous and difficult to quantify, mannose, galactose, N-acetylglycosamine and N- were used as constituent monosaccharides.
Acetylneuraminic acid was identified. The molar ratio was about 2.5: 1.4: 2.5: 2.1.

(d)等電点 ポリアクリルアミドゲル等電点電気泳動法及びシユクロ
ース密度勾配等電点電気泳動法により、等電点を測定し
た結果、pIは3.1〜3.7であつた。
(D) Isoelectric point The isoelectric point was measured by polyacrylamide gel isoelectric focusing method and sucrose density gradient isoelectric focusing method. As a result, pI was 3.1 to 3.7.

(e)円二色性(CD)スペクトル 円二色性分散計(JASCO社製J−600)で遠紫外部に於け
るCDスペクトルを測定した(第2図)。
(E) Circular dichroism (CD) spectrum The CD spectrum in the far ultraviolet region was measured with a circular dichroism dispersion meter (J-600 manufactured by JASCO) (Fig. 2).

図2は本発明のCSFのCDスペクトルを示し、横軸は波長
(nm)、縦軸は楕円率(mdeg)を示す。波長208nm及び2
22nmにおいて極少ピークがみとめられ、本CSFの二次構
造にα−ヘリツクス構造が含まれているものと推定され
た。
FIG. 2 shows the CD spectrum of the CSF of the present invention, the horizontal axis shows the wavelength (nm), and the vertical axis shows the ellipticity (mdeg). Wavelength 208nm and 2
A minimal peak was observed at 22 nm, and it was presumed that the secondary structure of this CSF contains an α-helix structure.

(f)熱安定性 本CSFを1μg/mlの濃度で、希薄緩衝液(pH7.0)に溶解
し、60±0.5℃で60分間加熱し、そのコロニー刺激活性
(後述)を測定したが、活性の低下はほとんど認められ
なかつた。
(F) Thermostability This CSF was dissolved in a dilute buffer (pH 7.0) at a concentration of 1 μg / ml and heated at 60 ± 0.5 ° C. for 60 minutes to measure its colony stimulating activity (described later). Almost no decrease in activity was observed.

(g)赤外線吸収スペクトル 本CSFの凍結乾燥粉末について透過測定法(KBr窓)によ
りフーリエ変換赤外分光装置(Nicolet社製5D×C)を
用いて測定した赤外線吸収スペクトルはに示すとおりで
あつた。第3図の横軸は波数(cm-1)を縦軸は透過率を
示す。
(G) Infrared absorption spectrum An infrared absorption spectrum of the freeze-dried powder of the present CSF measured by a Fourier transform infrared spectroscope (5D × C manufactured by Nicolet Co.) by a transmission measurement method (KBr window) is as shown in. . The horizontal axis of FIG. 3 represents the wave number (cm −1 ) and the vertical axis represents the transmittance.

本CSFは1650cm-1、1201cm-1及び1133cm-1に強い吸収、1
537cm-1、1432cm-1及び1068cm-1に中程度の吸収を示し
た。
This CSF is strong absorption in 1650cm -1, 1201cm -1 and 1133cm -1, 1
It showed moderate absorption at 537 cm -1 , 1432 cm -1 and 1068 cm -1 .

(3)CSFの生物学的活性 前記(2)項と同様に、このコロニー刺激活性及び比活
性の試験には、実施例1の方法により純化したCSFを用
いた。
(3) Biological activity of CSF In the same manner as in the above item (2), CSF purified by the method of Example 1 was used for this colony stimulating activity and specific activity test.

(a)コロニー刺激活性及び比活性 本発明のCSFのコロニー刺激活性は、マウス骨髄細胞に
よる単層軟寒天ゲルでのコロニー形成試験法で測定し
た。CSF試料を0.3%寒天、20%牛胎児血清(FCS)及び
マウス骨髄細胞1×105個を含むMcCoy′s5A培地1mlと混
合し、7.5%CO2通気下、37℃で7日間培養した。培養
後、50個以上の細胞集塊をコロニーと判定し、形成され
たコロニー数を計測した。コロニー刺激活性は単位で表
現し、1単位は1コロニーを形成させるに必要なCSF量
と規定した。また比活性は、CSF蛋白質1mg当り形成され
るコロニー数(単位)で表わした。その結果、本発明の
CSFは、1.4×108単位/mg・蛋白質の比活性を有してい
た。また形成されたコロニーをヘマトキシリン−エオジ
ン染色して形態学的に分類したところ、95%以上のコロ
ニーが単球−マクロフアージから形成されていた。
(A) Colony stimulating activity and specific activity The colony stimulating activity of the CSF of the present invention was measured by a colony formation test method using a mouse bone marrow cell on a monolayer soft agar gel. The CSF sample was mixed with 1 ml of McCoy's 5A medium containing 0.3% agar, 20% fetal calf serum (FCS) and 1 × 10 5 mouse bone marrow cells, and cultured at 37 ° C. under 7.5% CO 2 aeration for 7 days. After culturing, 50 or more cell aggregates were determined as colonies, and the number of formed colonies was counted. The colony stimulating activity was expressed in units, and one unit was defined as the amount of CSF required to form one colony. The specific activity was represented by the number of colonies (unit) formed per mg of CSF protein. As a result, the
CSF had a specific activity of 1.4 × 10 8 units / mg protein. When the formed colonies were morphologically classified by staining with hematoxylin-eosin, 95% or more of the colonies were formed from monocytes-macrophages.

(b)in vitro及びin vivoでのマウス骨髄単球−マク
ロフアージ系幹細胞(CFU−M)の増殖に及ぼす促進作
用 b−1)in vitro試験 C57BLマウスの骨髄細胞を平板吸着法にて、非吸着骨髄
細胞とし、20%FCSを含むMcCoy′s5A培地へ1×106個/m
lの濃度に添加し、本発明のCSFを0(対照)、100単位/
ml、500単位/ml、1,000単位/ml及び2,000単位/mlの割合
でそれぞれ加え、7.5%CO2通気下、24時間、37℃で培養
した。培養後、各骨髄細胞を遠心法で洗浄した後、同じ
培地で5倍に希釈し、各群4枚のシヤーレに、それぞれ
CSF1,000単位、0.3%寒天及び20%FCSを含むMcCoy′s5A
培地1mlに対して0.1ml添加し、7.5%CO2通気下、37℃で
7日間培養した。培養後、50個以上の細胞集塊を単球−
マクロフアージ系幹細胞(CFU−M)と判定し、形成さ
れたCFU−M数を計測した。その結果は表2に示すとお
りであつた。
(B) in vitro and mouse bone marrow monocytes in in vivo - in macrophages stem cell promoting effect on the growth of (CFU-M) b-1 ) in vitro test C 57 BL mouse bone marrow cells flat adsorption method, Non-adsorbed bone marrow cells in McCoy's 5A medium containing 20% FCS 1 × 10 6 cells / m
CSF of the present invention, 0 (control), 100 units /
ml, 500 units / ml, 1,000 units / ml and 2,000 units / ml, respectively, and the mixture was incubated at 37 ° C. for 24 hours under aeration of 7.5% CO 2 . After culturing, each bone marrow cell was washed by centrifugation, diluted 5 times with the same medium, and added to each four groups of scare.
McCoy's 5A with 1,000 units of CSF, 0.3% agar and 20% FCS
0.1 ml was added to 1 ml of the medium, and the mixture was cultured at 37 ° C. for 7 days under aeration of 7.5% CO 2 . After culturing, aggregate 50 or more cells into monocytes-
The cells were determined to be macrophage stem cells (CFU-M), and the number of CFU-M formed was counted. The results are shown in Table 2.

表2に示すようにCSFの添加濃度に依存して、マウス骨
髄細胞中のCFU−M数は増加した。
As shown in Table 2, the number of CFU-M in mouse bone marrow cells increased depending on the added concentration of CSF.

b−2)in vivo試験 C57BLマウス(5匹/群)に対して体重1kg当り0(生理
食塩液)、80×104単位、160×104単位及び320×104
位CSFを1日1回、連続3日間腹腔内に投与した。投与
終了の翌日に、各マウスにより大腿骨骨髄及び脾臓を摘
出し、骨髄及び脾臓中の単球−マクロフアージ系幹細胞
(CFU−M)数を、1,000単位のCSFを刺激因子とする前
記軟寒天平板法によるコロニー形成試験で測定した。そ
の結果は表3及び表4に示すとおりであつた。
b-2) In vivo test 0 (physiological saline) per 1 kg of body weight, 80 × 10 4 units, 160 × 10 4 units and 320 × 10 4 units CSF for C 57 BL mice (5 / group) 1 CSF It was administered intraperitoneally once a day for 3 consecutive days. On the day after the end of administration, the femur bone marrow and spleen were removed from each mouse, and the number of monocyte-macrophage stem cells (CFU-M) in the bone marrow and spleen was adjusted to 1,000 units of CSF as a stimulator. It was measured by a colony formation test by the method. The results are shown in Tables 3 and 4.

表3及び表4に示す如く、80×104単位/kg体重のCSF投
与により、骨髄及び脾臓でのCFU−Mの増加が認めら
れ、160×104単位/kg体重以上の投与では顕著な増加が
認められた。
As shown in Tables 3 and 4, an increase in CFU-M in the bone marrow and spleen was observed by the administration of 80 × 10 4 units / kg body weight of CSF, and it was remarkable in the administration of 160 × 10 4 units / kg body weight or more. An increase was observed.

以上のような理化学的性質及び生物学的活性を有する本
発明のCSFを公知の類似した物質と比較すると次のとお
りである。
The CSF of the present invention having the above physicochemical properties and biological activities is compared with the known similar substances as follows.

本発明のCSFは、CSF−1と同様に糖鎖を含む二本のポリ
ペプチドがジスルフイド結合し、生物学的に活性なホモ
2量体から構成されていて分子量は、70,000〜90,000ダ
ルトンであり、CSF−1のそれよりも大きい。更に、本
発明のCSFを構成しているサブユニツトのポリペプチド
は、少なくとも189個のアミノ酸から成り、分子量35,00
0〜45,000ダルトンであり、CSF−1のそれの14,000〜1
7,000ダルトンよりも大きい。また、サブユニツトのア
ミノ酸配列をCSF−1と比較すると、NH2−末端の1番か
ら149番目までのアミノ酸配列は同じであつたが、150番
から189番目までのアミノ酸配列はCSF−1のcDNAから推
定されるものと異なつており、CSF−1遺伝子上にコー
ドされていなかつた。従つて、本発明のCSFは、一部CSF
−1と共通性を有するが、遺伝子的にも、構造的にも、
公知のCSF−1とは別個な因子であることが判明した。
The CSF of the present invention is composed of a biologically active homodimer in which two polypeptides containing a sugar chain are disulphide-bonded like CSF-1, and has a molecular weight of 70,000 to 90,000 daltons. , Which is larger than that of CSF-1. Further, the subunit polypeptide constituting the CSF of the present invention consists of at least 189 amino acids and has a molecular weight of 35,00.
0-45,000 Daltons, 14,000-1 of that of CSF-1
Greater than 7,000 Daltons. When the amino acid sequence of the subunit was compared with that of CSF-1, the amino acid sequences from 1 to 149th at the NH 2 -terminal were the same, but the amino acid sequence from 150th to 189th was the cDNA of CSF-1. It was not encoded on the CSF-1 gene, which was different from that deduced from Therefore, the CSF of the present invention is partially CSF.
-1 has a commonality, but genetically and structurally
It was found to be a separate factor from the known CSF-1.

次に本発明の実施例を示す。Next, examples of the present invention will be described.

実施例1 健常人の尿200lをpH8.5に調整し、沈澱物を濾過除去
し、分画分子量50,000ダルトンの限外濾過膜(アミコン
社、H10×50)で濃縮と脱塩を行つた。次に、濃縮液をp
H7.0に調整し、密封容器中で60℃、10時間加熱殺菌し
た。殺菌後、遠心分離(5,000×g 30分間)して沈澱物
を除去した後、0.02Mリン酸緩衝液(pH7.2)で平衡化し
たDEAE−セルロースと混合し、吸着させた。DEAE−セル
ロースを0.02Mリン酸緩衝液、0.05M食塩添加0.02Mリン
酸緩衝液(pH7.2)で洗浄した後、0.25M食塩添加緩衝液
(pH7.2)で溶出させた。溶出液を限外濾過膜(アミコ
ン社H1P10)で濃縮して、Sephacryl S−300(フアルマ
シア社、φ4×80cm)を用い、1M硫安添加緩衝液(pH7.
2)でゲル濾過した。ゲル濾過での分子量範囲70,000〜1
50,000ダルトンの画分を上記1M硫安添加緩衝液で平衡化
したphenyl−Sepharose4Bカラム(フアルマシア社製、
φ2×20cm)に吸着させ、次いで0.5M硫安添加緩衝液
(pH7.2)で溶出させた。溶出液を限外濾過膜(旭化成
製、NM−3)で濃縮して、TSKG−3,000SWカラム(東洋
曹達製、φ4×600mm×2)で高速液体クロマトグラフ
イーにかけ、分子量範囲70,000〜150,000ダルトンの画
分を得た。この画分を再度濃縮し、Hi−Pore RP−304
(バイオラド社製、φ4×150mm)の逆相カラムで0.1%
トリフルオロ酢酸を含む、アセトニトリル0−100%(p
H2.0)の直線濃度勾配による高速液体クロマトグラフイ
ーにかけ、CSFを溶出し、精製された比活性1.4×108
位/mg・蛋白質のCSFを得た。上記製造工程の各ステツプ
におけるCSFの精製度は表5に示すとおりであつた。
Example 1 200 l of urine of a healthy person was adjusted to pH 8.5, the precipitate was removed by filtration, and concentrated and desalted with an ultrafiltration membrane (Amicon, H10 × 50) having a cutoff molecular weight of 50,000 daltons. Next, p
It was adjusted to H7.0 and sterilized by heating in a sealed container at 60 ° C for 10 hours. After sterilization, the precipitate was removed by centrifugation (5,000 xg for 30 minutes), and then mixed with DEAE-cellulose equilibrated with 0.02M phosphate buffer (pH 7.2) to adsorb. DEAE-cellulose was washed with 0.02 M phosphate buffer and 0.05 M salt-added 0.02 M phosphate buffer (pH 7.2), and then eluted with 0.25 M salt-added buffer (pH 7.2). The eluate was concentrated with an ultrafiltration membrane (H1P10 manufactured by Amicon) and Sephacryl S-300 (Pharmacia, φ4 × 80 cm) was used to add a 1 M ammonium sulfate addition buffer (pH 7.
Gel filtration was performed in 2). Molecular weight range for gel filtration 70,000-1
A phenyl-Sepharose 4B column (Falmatia,
φ2 × 20 cm) and then eluted with 0.5 M ammonium sulfate addition buffer (pH 7.2). The eluate was concentrated with an ultrafiltration membrane (Asahi Kasei, NM-3) and subjected to high performance liquid chromatography on a TSKG-3,000SW column (Toyo Soda, φ4 × 600mm × 2), molecular weight range 70,000-150,000 Daltons. Was obtained. This fraction was concentrated again and the Hi-Pore RP-304
0.1% on reverse phase column (Bio-Rad, φ4 × 150mm)
Acetonitrile containing trifluoroacetic acid 0-100% (p
H2.0) was subjected to high-performance liquid chromatography using a linear concentration gradient to elute CSF to obtain purified CSF having a specific activity of 1.4 × 10 8 units / mg protein. The degree of purification of CSF in each step of the above production process is shown in Table 5.

実施例2 実施例1の方法でSephacryl S−300をTSKG−3,000SW
(東洋曹達、HLC−837)、phenyl−Sepharose4BをTSKph
enyl−5pw(東洋曹達)にかえて、全く高速液体クロマ
トグラフイーにより精製した。得られたCSFは、比活性
1.5×108単位/mgであり、回収率も実施例1と同等であ
つた。
Example 2 Sephacryl S-300 was added to TSKG-3,000SW by the method of Example 1.
(Toyo Soda, HLC-837), phenyl-Sepharose 4B in TSKph
Instead of enyl-5pw (Toyo Soda), it was purified by high performance liquid chromatography. The obtained CSF has a specific activity
It was 1.5 × 10 8 units / mg, and the recovery rate was similar to that in Example 1.

【図面の簡単な説明】[Brief description of drawings]

第1図は本発明のCSFのドデシル硫酸ナトリウム・ポリ
アクリルアミド電気泳動(SDS−PAGE)の泳動図であ
り、第2図及び第3図はそれぞれ本発明CSFの遠紫外部C
Dスペクトル及び赤外線吸収スペクトルを示す。 第1図において、 A〜E……非還元物(2量体) F,G……分子量マーカ蛋白質 H〜L……還元物(サブユニツト)
FIG. 1 is a migration diagram of CSF of the present invention by sodium dodecyl sulfate / polyacrylamide gel electrophoresis (SDS-PAGE), and FIGS. 2 and 3 are far-far ultraviolet C of the CSF of the present invention.
The D spectrum and the infrared absorption spectrum are shown. In Fig. 1, A to E ... non-reduced products (dimers) F, G ... molecular weight marker proteins H to L ... reduced products (subunit)

───────────────────────────────────────────────────── フロントページの続き (72)発明者 柳内 延也 東京都中野区南台5−21−10 森永乳業株 式会社中野社宅401 (72)発明者 山田 宗夫 神奈川県川崎市高津区久地752 栄テラス 205号 (72)発明者 横田 肇 東京都港区白金2−5−1−406 (56)参考文献 国際公開87/6954(WO,A) ─────────────────────────────────────────────────── ─── Continuation of front page (72) Inventor Nobuya Yanagiuchi 5-21-10 Minamidai, Nakano-ku, Tokyo Morinaga Milk Industry Co., Ltd. Nakanosha's house 401 (72) Inventor, Muneo Yamada 752, Kuji, Takatsu-ku, Kawasaki-shi, Kanagawa Terrace 205 (72) Inventor Hajime Yokota Hajime 2-5-1-406 Shirokane, Minato-ku, Tokyo (56) References International Publication 87/6954 (WO, A)

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】哺乳動物の単球−マクロファージ系細胞の
コロニー形成刺激作用を有し、次の理化学的性質を有す
ることを特徴とするコロニー刺激糖蛋白質: a)分子量 同一のサブユニット2個から成るホモ2量体であって、
ドデシル硫酸ナトリウム・ポリアクリルアミドゲル電気
泳動で測定した分子量が70,000〜90,000ダルトンであ
り、還元剤で解離させて生物活性を消失させたサブユニ
ットについてドデシル硫酸ナトリウム・ポリアクリルア
ミドゲル電気泳動で測定した分子量は、35,000〜45,000
ダルトンである; b)サブユニットのアミノ酸配列 ホモ2量体を構成するサブユニット蛋白質は、以下に示
す少なくとも189個のアミノ酸配列から成り、122番目及
び140番目のアスパラギン(Asn)はそれぞれアスパラギ
ン(Asn)−X−スレオニン(Thr)/セリン(Ser)で
表わされるN−グリコシド結合部位を有し、ここでXは
任意のアミノ酸を示す; c)等電点 ポリアクリルアミドゲル等電点電気泳動法及びシュクロ
ース密度勾配等電点電気泳動法で測定した等電点(pI)
は3.1〜3.7である; d)糖鎖の構成単糖 加水分解後、高速液体クロマトグラフィーで分析により
同定された糖鎖の構成単糖は、マンノース、ガラクトー
ス、N−アセチルグルコサミン及びN−アセチルノイラ
ミン酸である; e)円二色性スペクトル 円二色性分散計による遠紫外部CDスペクトルは波長208n
m及び222nmにそれぞれ極少ピークがあり、α−ヘリック
ス構造を含んでいる; f)熱安定性 60±0.5℃で60分間加熱しても生物活性は失なわれな
い; g)赤外線吸収スペクトル 赤外線吸収スペクトルにおいて、1650cm-1、1201cm-1
び1133cm-1に強い吸収、1537cm-1、1432cm-1及び1068cm
-1に中程度の吸収を示す; h)比活性 1.4×108単位/mg・蛋白質以上の比活性を示す。
1. A colony-stimulating glycoprotein characterized by having a colony-forming stimulatory effect on mammalian monocyte-macrophage cells and having the following physicochemical properties: a) From two subunits having the same molecular weight A homodimer consisting of
The molecular weight measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis is 70,000 to 90,000 daltons, and the molecular weight measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the subunit dissociated with a reducing agent to eliminate biological activity is , 35,000 to 45,000
It is Dalton; b) Amino acid sequence of subunit The subunit protein that constitutes the homodimer consists of at least 189 amino acid sequences shown below, and the 122nd and 140th asparagine (Asn) are asparagine (Asn), respectively. ) -X-threonine (Thr) / serine (Ser) has an N-glycoside binding site, wherein X represents an arbitrary amino acid; c) Isoelectric point Isoelectric point (pI) measured by polyacrylamide gel isoelectric focusing method and sucrose density gradient isoelectric focusing method
Is from 3.1 to 3.7; d) Constituent monosaccharide of sugar chain The constituent monosaccharide of sugar chain identified by analysis by high performance liquid chromatography after hydrolysis is mannose, galactose, N-acetylglucosamine and N-acetyl neu. It is laminic acid; e) Circular dichroism spectrum The far-UV CD spectrum measured by a circular dichroism disperser is 208n
It has a minimum peak at m and 222 nm, and contains an α-helix structure; f) Thermal stability No biological activity is lost by heating at 60 ± 0.5 ° C for 60 minutes; g) Infrared absorption spectrum Infrared absorption in the spectrum, 1650 cm -1, strong absorption at 1201cm -1 and 1133cm -1, 1537cm -1, 1432cm -1 and 1068cm
-1 shows moderate absorption; h) Specific activity 1.4 × 10 8 units / mg.
【請求項2】人尿をpH8〜9に調整し、不溶物を沈殿せ
しめ、その上澄を限外濾過膜で脱塩し、少なくとも200
倍以上に濃縮した後、pHを6.5〜7.5に調整し、60℃で10
時間加熱処理し、沈殿物を遠心除去後、陰イオン交換体
に吸着させ、0.2〜0.4M緩衝液で溶出させ、次いで1〜4
M緩衝液中でゲル濾過して分子量70,000ダルトン以上の
画分を回収し、該画分を疎水性親和体に吸着させ、0.5
〜1Mの緩衝液で溶出させ、該溶出物を高速液体ゲル濾過
にかけ、分子量70,000〜150,000ダルトンの画分を回収
し、該画分をpH1〜2に調整して逆相高速液体クロマト
グラフィーにかけ、有効成分を溶出せしめることを特徴
とする、哺乳動物の単球−マクロファージ系細胞のコロ
ニー形成刺激作用を有し次の理化学的性質を有するコロ
ニー刺激糖蛋白質の製造法: a)分子量 同一のサブユニット2個から成るホモ2量体であって、
ドデシル硫酸ナトリウム・ポリアクリルアミドゲル電気
泳動で測定した分子量が70,000〜90,000ダルトンであ
り、還元剤で解離させて生物活性を消失させたサブユニ
ットについてドデシル硫酸ナトリウム・ポリアクリルア
ミドゲル電気泳動で測定した分子量は、35,000〜45,000
ダルトンである; b)サブユニットのアミノ酸配列 ホモ2量体を構成するサブユニット蛋白質は、以下に示
す少なくとも189個のアミノ酸配列から成り、122番目及
び140番目のアスパラギン(Asn)はそれぞれアスパラギ
ン(Asn)−X−スレオニン(Thr)/セリン(Ser)で
表わされるN−グリコシド結合部位を有し、ここでXは
任意のアミノ酸を示す; c)等電点 ポリアクリルアミドゲル等電点電気泳動法及びシュクロ
ース密度勾配等電点電気泳動法で測定した等電点(pI)
は3.1〜3.7である; d)糖鎖の構成単糖 加水分解後、高速液体クロマトグラフィーで分析により
同定された糖鎖の構成単糖は、マンノース、ガラクトー
ス、N−アセチルグルコサミン及びN−アセチルノイラ
ミン酸である; e)円二色性スペクトル 円二色性分散計による遠紫外部CDスペクトルは波長208n
m及び222nmにそれぞれ極少ピークがあり、α−ヘリック
ス構造を含んでいる; f)熱安定性 60±0.5℃で60分間加熱しても生物活性は失なわれな
い; g)赤外線吸収スペクトル 赤外線吸収スペクトルにおいて、1650cm-1、1201cm-1
び1133cm-1に強い吸収、1537cm-1、1432cm-1及び1068cm
-1に中程度の吸収を示す; h)比活性 1.4×108単位/mg・蛋白質以上の比活性を示す。
2. Human urine is adjusted to pH 8 to 9 to precipitate insoluble matter, and the supernatant is desalted with an ultrafiltration membrane to obtain at least 200
After concentrating more than twice, adjust the pH to 6.5-7.5 and
After heat treatment for an hour, the precipitate is removed by centrifugation, adsorbed on an anion exchanger and eluted with a 0.2 to 0.4 M buffer, and then 1 to 4
Gel filtration in M buffer was performed to collect a fraction having a molecular weight of 70,000 daltons or more, and the fraction was adsorbed on a hydrophobic affinity substance,
Elute with ~ 1M buffer, subject the eluate to high performance liquid gel filtration to collect a fraction having a molecular weight of 70,000 to 150,000 daltons, adjust the fraction to pH 1-2 to perform reverse phase high performance liquid chromatography, Method for producing colony-stimulating glycoprotein having the following physicochemical properties, which has a colony-forming stimulatory action on mammalian monocyte-macrophage lineage cells, characterized in that an active ingredient is eluted: a) Subunits having the same molecular weight A homodimer consisting of two,
The molecular weight measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis is 70,000 to 90,000 daltons, and the molecular weight measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the subunit dissociated with a reducing agent to eliminate biological activity is , 35,000 to 45,000
It is Dalton; b) Amino acid sequence of subunit The subunit protein that constitutes the homodimer consists of at least 189 amino acid sequences shown below, and the 122nd and 140th asparagine (Asn) are asparagine (Asn), respectively. ) -X-threonine (Thr) / serine (Ser) has an N-glycoside binding site, wherein X represents an arbitrary amino acid; c) Isoelectric point Isoelectric point (pI) measured by polyacrylamide gel isoelectric focusing method and sucrose density gradient isoelectric focusing method
Is from 3.1 to 3.7; d) Constituent monosaccharide of sugar chain The constituent monosaccharide of sugar chain identified by analysis by high performance liquid chromatography after hydrolysis is mannose, galactose, N-acetylglucosamine and N-acetyl neu. It is laminic acid; e) Circular dichroism spectrum The far-UV CD spectrum measured by a circular dichroism disperser is 208n
It has a minimum peak at m and 222 nm, and contains an α-helix structure; f) Thermal stability No biological activity is lost by heating at 60 ± 0.5 ° C for 60 minutes; g) Infrared absorption spectrum Infrared absorption in the spectrum, 1650 cm -1, strong absorption at 1201cm -1 and 1133cm -1, 1537cm -1, 1432cm -1 and 1068cm
-1 shows moderate absorption; h) Specific activity 1.4 × 10 8 units / mg.
JP61291294A 1986-12-07 1986-12-07 Colony-stimulating factor and method for producing the same Expired - Fee Related JPH07100719B2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP61291294A JPH07100719B2 (en) 1986-12-07 1986-12-07 Colony-stimulating factor and method for producing the same
AU82181/87A AU606099B2 (en) 1986-12-07 1987-12-07 Colony-stimulating factor and method for preparation thereof
DE8787310739T DE3777623D1 (en) 1986-12-07 1987-12-07 COLONY-STIMULATING FACTOR AND METHOD FOR PRODUCING THE SAME.
AT87310739T ATE73825T1 (en) 1986-12-07 1987-12-07 COLONY STIMULATING FACTOR AND METHOD FOR ITS PRODUCTION.
EP87310739A EP0276551B1 (en) 1986-12-07 1987-12-07 Colony-stimulating factor and method for preparation thereof
KR1019880003849A KR960005731B1 (en) 1986-12-07 1988-04-06 Colony-stimulating factor and the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP61291294A JPH07100719B2 (en) 1986-12-07 1986-12-07 Colony-stimulating factor and method for producing the same

Publications (2)

Publication Number Publication Date
JPS63198700A JPS63198700A (en) 1988-08-17
JPH07100719B2 true JPH07100719B2 (en) 1995-11-01

Family

ID=17767023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61291294A Expired - Fee Related JPH07100719B2 (en) 1986-12-07 1986-12-07 Colony-stimulating factor and method for producing the same

Country Status (1)

Country Link
JP (1) JPH07100719B2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3023248B2 (en) * 1992-09-10 2000-03-21 キヤノン株式会社 Position detection device

Also Published As

Publication number Publication date
JPS63198700A (en) 1988-08-17

Similar Documents

Publication Publication Date Title
US4444760A (en) Purification and characterization of a protein fibroblast growth factor
JP2579981B2 (en) M-CSF production method
AU590543B2 (en) Purification of native colony stimulating factor-1
EP0276551B1 (en) Colony-stimulating factor and method for preparation thereof
US5792450A (en) Purified human CSF-1
KR0131204B1 (en) Adjuvant for cancer theraphy
US5895646A (en) Isolated native primate GM-CSF protein
KR20040071212A (en) Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
JPS6236326A (en) Remedy for disease of hematopoietic organ
EP0550769B1 (en) Use of hepatocyte growth factors for the manufacture of a hemopoietic stem cell augmenting agent
EP0373540A2 (en) Method for purifying fibroblast growth factor protein
EP0328132B1 (en) Therapeutic agent for thrombocytopenia
JPH07100719B2 (en) Colony-stimulating factor and method for producing the same
US7311903B2 (en) Glycosylated human interferon alpha isoform
CA2050318A1 (en) Endothelial cell growth factor, methods of isolation and expression
IE910916A1 (en) Method for enhanced growth and proliferation of mast cells
US5391706A (en) Purification of GM-CSF
EP0573904B1 (en) Therapeutic agent for neutropenia
KR20040083268A (en) Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof
JPH07100720B2 (en) Method for producing colony stimulating factor
JPS63250400A (en) Colony stimulating factor and production thereof
EP0331088A2 (en) Remedy for hematopoietic tissue diseases comprising human monocytic macrophage colony stimulating factor as active ingredient
JPH07103041B2 (en) Malignant tumor treatment adjuvant
JP3580836B2 (en) Neutropenia treatment agent
EP0178050A1 (en) Proteinaceous substance

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees